ConductScience.org, home

Paper26817023

Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice.

Damme M and 11 others. Ann Clin Transl Neurol, 2015. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice. Papers, record 26817023. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26817023

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice.
PubMed
Journal
Ann Clin Transl Neurol
PubMed
Year
2015
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.28
iCite
Revised in PubMed
2018-11-13
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Damme MMarkus
2Stroobants SStijn
3Lüdemann MMeike
4Rothaug MMichelle
5Lüllmann-Rauch RRenate
6Beck HCHans Christian
7Ericsson AAnnika
8Andersson CClaes
9Fogh JJens
10D'Hooge RRudi
11Saftig PPaul
12Blanz JJudith

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References54

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14979627Mannosidosis: a clinical and histopathologic study.J Pediatr1969https://conductscience.org/library/papers/4979627PubMed
211179018A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.Am J Hum Genet2001https://conductscience.org/library/papers/11179018PubMed
312700165Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase.Hum Mol Genet2003https://conductscience.org/library/papers/12700165PubMed
423494656Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study.J Inherit Metab Dis2013https://conductscience.org/library/papers/23494656PubMed
5197212Mannosidosis: pathology of the nervous system.J Neuropathol Exp Neurol1977https://conductscience.org/library/papers/197212PubMed
616211561Human and mouse microglia express connexin36, and functional gap junctions are formed between rodent microglia and neurons.J Neurosci Res2005https://conductscience.org/library/papers/16211561PubMed
722161967Identification of 83 novel alpha-mannosidosis-associated sequence variants: functional analysis of MAN2B1 missense mutations.Hum Mutat2012https://conductscience.org/library/papers/22161967PubMed
810657992Enzyme replacement therapy in a mouse model of aspartylglycosaminuria.FASEB J2000https://conductscience.org/library/papers/10657992PubMed
921946346Enzyme replacement therapy for lysosomal storage diseases.Curr Opin Pediatr2011https://conductscience.org/library/papers/21946346PubMed
1022388935Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age.Hum Mol Genet2012https://conductscience.org/library/papers/22388935PubMed
114967547Deficiency of beta-galactosidase and alpha-mannosidase--primary enzyme defects in gargoylism and a new generalized disease?Acta Paediatr Scand1967https://conductscience.org/library/papers/4967547PubMed
1217942826Dose translation from animal to human studies revisited.FASEB J2008https://conductscience.org/library/papers/17942826PubMed
1319174759Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy.Mol Ther2009https://conductscience.org/library/papers/19174759PubMed
1411439963Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.N Engl J Med2001https://conductscience.org/library/papers/11439963PubMed
156996438The vascular system of the cerebral cortex.Adv Anat Embryol Cell Biol1980https://conductscience.org/library/papers/6996438PubMed
1623027951Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/23027951PubMed
1722704978
Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.
Mol Genet Metab2012https://conductscience.org/library/papers/22704978PubMed
189915946Spectrum of mutations in alpha-mannosidosis.Am J Hum Genet1999https://conductscience.org/library/papers/9915946PubMed
1915979029Short-term, high dose enzyme replacement therapy in sialidosis mice.Mol Genet Metab2005https://conductscience.org/library/papers/15979029PubMed
203315809Trafficking of lysosomal enzymes.FASEB J1987https://conductscience.org/library/papers/3315809PubMed

See all 54 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
35706761Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases.GEN Biotechnol2022https://conductscience.org/library/papers/35706761PubMed
32517081The Role of Hematopoietic Cell Transplant in the Glycoprotein Diseases.Cells2020https://conductscience.org/library/papers/32517081PubMed
31282275Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis.Autophagy2020https://conductscience.org/library/papers/31282275PubMed
31040271The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells.Nat Commun2019https://conductscience.org/library/papers/31040271PubMed
29772816Alpha-Mannosidosis: Therapeutic Strategies.Int J Mol Sci2018https://conductscience.org/library/papers/29772816PubMed
27491075A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease.Dis Model Mech2016https://conductscience.org/library/papers/27491075PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26817023

GET https://conductscience.org/api/papers/v1/26817023/references?page=2